FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980852511> ?p ?o ?g. }

• W2980852511 endingPage "1526" @default.
• W2980852511 startingPage "1526" @default.
• W2980852511 abstract "Abstract Treatment for elderly AML patients who are unfit for intensive chemotherapy remains challenging. Induction with hypomethylating agents (HMA) are the most commonly used approach, however the rate of complete remission (CR) is only around 20% and median survival of 7-12 months. Clearly how to improve the clinical outcome in this patient population is an unmet need. Immunotherapy is promising in cancer treatment. A recent study demonstrated that HMA enhanced PD-1 pathway in MDS and AML patients (Yang et al., Leukemia 2014), suggesting a role of combining HMA and immunotherapy in leukemia therapeutics. To optimize this strategy, it is crucial to understand the interaction between HMA and immune response in AML. Here we performed both phenotypic and functional analysis on clinical samples collected from AML patients undergoing treatment of decitabine (DAC), a broadly used HMA. We aim to determine 1) how DAC influences the immune system; and 2) whether the immune status in AML patients predict the response to DAC treatment. Total of 22 peripheral blood samples from 11 AML patients receiving DAC were examined. Samples were collected at the time of prior to and 1-month post DAC treatment. We conducted a comprehensive phenotypic analysis of immune markers characterizing each immune component (T cells, B cells, NK, NKT, monocytes, myeloid-derived suppressor cells, and dendritic cells) and expression patterns of co-stimulatory or inhibitory molecules. In addition, perforin, granzyme B and cytokine release in response to anti-CD3/CD28 stimulation were examined to determine the functional status of T cells. A total of 45 markers separated in 8 overlapped staining panels were tested by flow cytometry. We first assessed the impact of DAC on the immune response in AML. Comparing the paired samples prior to vs. post treatment from the same patients, we observed an increase of the percentage of NK cells, as well as their expression of granzyme B and perforin upon DAC treatment. In contrast, DAC appears to cause CD8 T cell suppression as CD8 T cells from post-DAC samples showed higher PD-1 expression whereas lower IFN-γ production. We next investigated the predictive value of immune status for the response to DAC treatment. Among the 18 evaluable samples, we defined 10 responders (CR/Cri/PR) vs. 8 non-responders (treatment failure) based on the ELN 2017 recommendations. The correlation of immune characteristics to the clinical response was carefully examined. We started with an unsupervised principal component analysis (PCA), which revealed a distinguished pattern between the responders and non-responders (Fig. 1A). This encouraging observation suggests an association of immune signature to clinical outcome. Subsequent analysis demonstrated a major contribution of CD8 T cells to the association. We then focused on the phenotypic and functional analysis of CD8 T cells in responders vs. non-responders. We found a significantly higher percentage of terminal differentiated cells in non-responders compared with that of responders. Importantly, in the perspective of phenotypes, hierarchical clustering on markers of CD8 T cells divided samples into two major clades, 7 of 8 samples (87.5%) were responders on one branch and 7 of 10 samples (70%) were non-responders on the other. Most responders expressed lower frequency of inhibitory receptors and higher frequency of stimulatory receptors, whereas non-responders showed the opposite trend (Fig. 1B). The significant difference of these receptors was validated in paired t test analysis. Functional studies also showed more IFN-γ production in responders. Interestingly the intracellular staining of perforin and granzyme B was higher in non-responders, likely due to exhausted T cells that are unable to release these particles extracellularly. Collectively, our study discovered the vital role of the immune signature in predicting clinical outcome in AML. High functional CD8 T cell status, manifested by more capability of IFN-γ production, enhanced stimulatory molecule and low inhibitory receptor expression, associated with effective clinical response to DAC treatment. In addition, CD8 T cell function was down-regulated upon DAC treatment. Our results provide a strong rationale for integrating immunotherapy into HMA treatment in AML, also highlight the importance of immune signature analysis in the future trial design for this clinical setting. Disclosures No relevant conflicts of interest to declare." @default.
• W2980852511 created "2019-10-25" @default.
• W2980852511 creator A5001768894 @default.
• W2980852511 creator A5004302802 @default.
• W2980852511 creator A5004613974 @default.
• W2980852511 creator A5024693198 @default.
• W2980852511 creator A5051858382 @default.
• W2980852511 creator A5055657540 @default.
• W2980852511 creator A5059838967 @default.
• W2980852511 creator A5065589058 @default.
• W2980852511 creator A5065698591 @default.
• W2980852511 creator A5079889215 @default.
• W2980852511 creator A5085995024 @default.
• W2980852511 creator A5087920688 @default.
• W2980852511 date "2018-11-29" @default.
• W2980852511 modified "2023-09-28" @default.
• W2980852511 title "Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML" @default.
• W2980852511 doi "https://doi.org/10.1182/blood-2018-99-113547" @default.
• W2980852511 hasPublicationYear "2018" @default.
• W2980852511 type Work @default.
• W2980852511 sameAs 2980852511 @default.
• W2980852511 citedByCount "0" @default.
• W2980852511 crossrefType "journal-article" @default.
• W2980852511 hasAuthorship W2980852511A5001768894 @default.
• W2980852511 hasAuthorship W2980852511A5004302802 @default.
• W2980852511 hasAuthorship W2980852511A5004613974 @default.
• W2980852511 hasAuthorship W2980852511A5024693198 @default.
• W2980852511 hasAuthorship W2980852511A5051858382 @default.
• W2980852511 hasAuthorship W2980852511A5055657540 @default.
• W2980852511 hasAuthorship W2980852511A5059838967 @default.
• W2980852511 hasAuthorship W2980852511A5065589058 @default.
• W2980852511 hasAuthorship W2980852511A5065698591 @default.
• W2980852511 hasAuthorship W2980852511A5079889215 @default.
• W2980852511 hasAuthorship W2980852511A5085995024 @default.
• W2980852511 hasAuthorship W2980852511A5087920688 @default.
• W2980852511 hasConcept C104317684 @default.
• W2980852511 hasConcept C126322002 @default.
• W2980852511 hasConcept C143998085 @default.
• W2980852511 hasConcept C150194340 @default.
• W2980852511 hasConcept C167672396 @default.
• W2980852511 hasConcept C190727270 @default.
• W2980852511 hasConcept C203014093 @default.
• W2980852511 hasConcept C2776012956 @default.
• W2980852511 hasConcept C2776239401 @default.
• W2980852511 hasConcept C2777701055 @default.
• W2980852511 hasConcept C2778729363 @default.
• W2980852511 hasConcept C2780235182 @default.
• W2980852511 hasConcept C2780380082 @default.
• W2980852511 hasConcept C2908647359 @default.
• W2980852511 hasConcept C55493867 @default.
• W2980852511 hasConcept C71924100 @default.
• W2980852511 hasConcept C86803240 @default.
• W2980852511 hasConcept C8891405 @default.
• W2980852511 hasConcept C99454951 @default.
• W2980852511 hasConceptScore W2980852511C104317684 @default.
• W2980852511 hasConceptScore W2980852511C126322002 @default.
• W2980852511 hasConceptScore W2980852511C143998085 @default.
• W2980852511 hasConceptScore W2980852511C150194340 @default.
• W2980852511 hasConceptScore W2980852511C167672396 @default.
• W2980852511 hasConceptScore W2980852511C190727270 @default.
• W2980852511 hasConceptScore W2980852511C203014093 @default.
• W2980852511 hasConceptScore W2980852511C2776012956 @default.
• W2980852511 hasConceptScore W2980852511C2776239401 @default.
• W2980852511 hasConceptScore W2980852511C2777701055 @default.
• W2980852511 hasConceptScore W2980852511C2778729363 @default.
• W2980852511 hasConceptScore W2980852511C2780235182 @default.
• W2980852511 hasConceptScore W2980852511C2780380082 @default.
• W2980852511 hasConceptScore W2980852511C2908647359 @default.
• W2980852511 hasConceptScore W2980852511C55493867 @default.
• W2980852511 hasConceptScore W2980852511C71924100 @default.
• W2980852511 hasConceptScore W2980852511C86803240 @default.
• W2980852511 hasConceptScore W2980852511C8891405 @default.
• W2980852511 hasConceptScore W2980852511C99454951 @default.
• W2980852511 hasIssue "Supplement 1" @default.
• W2980852511 hasLocation W29808525111 @default.
• W2980852511 hasOpenAccess W2980852511 @default.
• W2980852511 hasPrimaryLocation W29808525111 @default.
• W2980852511 hasRelatedWork W1998703095 @default.
• W2980852511 hasRelatedWork W2054507167 @default.
• W2980852511 hasRelatedWork W2077778517 @default.
• W2980852511 hasRelatedWork W2167485228 @default.
• W2980852511 hasRelatedWork W2436188093 @default.
• W2980852511 hasRelatedWork W2803418633 @default.
• W2980852511 hasRelatedWork W3180148659 @default.
• W2980852511 hasRelatedWork W3203236595 @default.
• W2980852511 hasRelatedWork W4205740160 @default.
• W2980852511 hasRelatedWork W4286817035 @default.
• W2980852511 hasVolume "132" @default.
• W2980852511 isParatext "false" @default.
• W2980852511 isRetracted "false" @default.
• W2980852511 magId "2980852511" @default.
• W2980852511 workType "article" @default.